Trial results

A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

NCT06884293 on ClinicalTrials.gov · last registry update 2026-05-12

Closed to new participants; the 479 already enrolled are still being followed. Due to report 31 December 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: percentage change in body weight from baseline. Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is approved in the US, but not for mash nafld — a registration here is not an approval, and most drugs tested in a new condition never get one for it.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.

Sponsor type

Industry

Enrollment

479

Started

2025-05-09

Primary completion

2026-12-31 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

percentage change in body weight from baseline

Conditions studied

Overweight · Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.